Samsung Biologics collaborates with Dinona for potential COVID-19 treatment

▴ Samsung Biologics collaborates with Dinona for potential COVID-19 treatment
Under this agreement, Samsung and Dinona will collaborate for fast-track development of DNP-019, a potential COVID-19 antibody therapy

Samsung Biologics has entered into a partnership agreement with biotech Dinona, further expanding its CDO capabilities to provide a full scope of its development services from cell line development, process development, to non-clinical and clinical material manufacturing. Under this agreement, Samsung and Dinona will collaborate for fast-track development of DNP-019, a potential COVID-19 antibody therapy.

Since its inception, the Samsung Biologics CDO business has been growing at a rapid pace with near 60 contracts signed in just two years. The business segment continues to expand its market reach through a cumulative track record of various biologics products beyond monoclonal antibodies and by targeting diverse treatment areas including cancer, neurodegenerative diseases, and as with this partnership, COVID-19 treatment.

Samsung Biologics has also recently introduced its proprietary cell-line technology, S-CHOice, this year showing improved titers up to two-fold from the industry average and maintaining over 90% cell viability. With a customized development strategy, Samsung Biologics has showcased a record of achievements in recent years. The company has dramatically reduced the time required for the development stage, taking six months to clinical material manufacturing and seven months to DP release.

“Samsung Biologics is always committed to providing the highest quality services to our clients globally to help biotech companies like Dinona focus on their core business, which is drug discovery,” said Tae Han Kim, CEO Samsung Biologics. “As with all our partnerships, we will closely collaborate with our client Dinona to provide the highest client satisfaction and support in its endeavor to bring a potential COVID-19 treatment to market faster and better.”

Tags : #SamsungBiologics #LatestNewsonSamsungBiologics22ndOct #Dinona #LatestNewsonDinona22ndOct #LatestPharmaCollaborationNews22ndOct #LatestPharmaNews22ndOct #LatestNewsonCOVIDVaccine22ndOct #TaeHanKim #AntibodyTherapyforCOVID-19

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-



Trending Now

Actor-Director Sathish Kaushik Died of a Heart Attack at the Age of 66March 09, 2023
Soleus Push-Ups: A Laziest Exercise to Lower Blood Sugar LevelsMarch 09, 2023
World Kidney Day 2023: Be Aware of Kidney DiseasesMarch 09, 2023
Sushmita Sen reveals about suffering from a severe heart attack recently and Addison's disease in 2014March 06, 2023
A significant increase in influenza A H3N2 patients that are accompanied by severe coughing and feverMarch 06, 2023
Is AIDS or HIV curable in Ayurveda?March 03, 2023
Artificial Sweetener Erythritol Raises the Possibility of Heart Attack.March 01, 2023
Difference between HIV and AIDS - When to give antiretroviral therapy?March 01, 2023
Zero Discrimination Day: Let's Raise the Voice Against DiscriminationMarch 01, 2023
International Women’s Day 2023 – Embrace EquityFebruary 28, 2023
Brain Tumors - Types, Symptoms and Risk FactorsFebruary 28, 2023
World Rare Disease Day: End Stigma Against Rare Diseases.February 28, 2023
National Science Day 2023 - Global Science for Global WellbeingFebruary 28, 2023
Eating disorders - Types and their complicationsFebruary 27, 2023
The condition that took away the life of Malayalam filmmaker, Joseph ManuFebruary 27, 2023
World NGO Day 2023 - We make a living by what we get, but we make a life by what we giveFebruary 27, 2023
Functions and Problems of SerotoninFebruary 25, 2023
Arthritis management – Tips to manage arthritis effectivelyFebruary 25, 2023
Apple has undertaken a project of no-prick blood sugar monitoring feature for its watch.February 24, 2023
Bird flu – Jharkhand on alert, know its prevention and symptoms in humansFebruary 24, 2023